IceCure Medical Ltd. (ICCM) Stock Analysis and Metrics

IceCure Medical

NASDAQ: ICCM

$3.05 ▼ -0.18 (-5.57%)

At close: Jul 24, 2026 · 3:58 PM UTC

Financial Ratios

Market Cap7.92 Mn

P/E0.50

P/S2.22

Div. Yield0.00

Revenue Growth (1y) (Qtr)25.66

Add ratio to table…

About

IceCure Medical Ltd. is a commercial stage medical device company that develops and commercializes cryoablation systems using liquid nitrogen to ablate benign and malignant tumors. The company's flagship product is the ProSense system which has received FDA marketing authorization for treating low risk breast cancer in women aged 70 and above who receive adjuvant endocrine therapy. IceCure also offers the IceSense3 and XSense systems and is developing the MSense platform along with disposable probes and introducers that are used with its systems.

IceCure generates revenue primarily from the sale of its cryoablation systems and disposable probes to distributors and end users as well as from service and maintenance contracts for its equipment. The company follows a razor/razor blade model where recurring revenue comes from the sale of single use probes tied to the number of procedures performed. Additionally IceCure may place systems with customers who commit to purchasing a minimum volume of disposables over time.

IceCure operates in the competitive cryoablation and tumor ablation market alongside larger medical device firms such as Galil Medical a Boston Scientific subsidiary EndoCare a Siemens Healthineers subsidiary and Sanarus part of Hologic. The company differentiates itself through its liquid nitrogen based technology which achieves lower freezing temperatures than argon based systems leading to faster tumor destruction less patient pain reduced anesthesia needs and clearer intra procedural imaging. These technical advantages support IceCure's position as a niche innovator in minimally invasive cancer treatment.

IceCure's customers include hospitals ambulatory surgical centers private clinics and distributors that resell its products. In the United States the primary users are breast surgeons interventional radiologists and breast radiologists who perform cryoablation procedures. The company also works with distribution partners such as Terumo in Japan and Thailand and various regional distributors in Europe Asia and Latin America to reach end users.

Investment Thesis

▲ Bull case

The company reported a 26% year over year increase in total revenue for Q1 FY26 driven by new system placements and rising disposable probe sales indicating strong demand generation. North America sales surged 84% year over year with U.S. revenue up 31% year over year showing that the recent FDA clearance for low risk early breast cancer is translating into immediate commercial traction. The active U.S. account base expanded to 19 sites representing a 46% increase from the pre FDA clearance baseline of 13 accounts reflecting successful conversion of leads into paying customers. Management highlighted a robust pipeline of qualified leads generated at recent breast imaging and breast surgeon conferences which were significantly higher than in 2025 suggesting continued account growth in upcoming quarters.
The commercial organization is expanding through targeted hiring of sales representatives to increase geographic coverage and support the conversion of the growing lead pipeline into system installations. This expansion is designed to capture additional share within existing large health system networks where multiple units can be placed per account creating a recurring revenue stream from disposable probe usage. The company reported rising procedural activity at both new and existing sites which is a leading indicator of long term adoption and sticky revenue. By leveraging a model that does not require additional infrastructure or complex integration ProSense can be deployed quickly in outpatient clinics and community hospitals accelerating site onboarding.
The Choice post market study received FDA approval in March 2026 and will enroll 30 hybrid clinical and commercial sites across the United States with first patient enrollment expected before September 5 2026 and a target of 80 patients by March 2027. Approximately half of the planned sites are already active commercial accounts which reduces site activation risk and accelerates data collection. The study is designed to generate real world evidence that will confirm and potentially expand the indications granted by the ICE3 trial thereby strengthening the reimbursement narrative. Positive outcomes from the Choice study could facilitate broader guideline adoption and support future CPT1 and transitional pass through payment applications.
Reimbursement prospects are advancing with an established CPT code covering facility costs of about $4,000 per procedure and a CPT1 code submission planned for June 2026 with a decision anticipated in early 2027. An application for an additional $9,000 transitional pass through payment has been submitted and if approved would provide supplementary Medicare reimbursement starting in early 2027. The company expects Health Canada clearance before year end 2026 and Japan PMDA submission by Turumo in June or early Q3 FY26 with very positive pre submission discussions indicating a favorable outlook. Successful international approvals would open new high growth markets and diversify revenue beyond the United States.
Physician adoption is being bolstered by updated guidelines from the American Society of Breast Surgeons and the American Society of Breast Radiologists which now recommend cryoablation as an option for selected low risk breast cancer patients. Dr Richard Fine noted that in the absence of full reimbursement the overall procedure cost remains low enough for patients to manage an out of pocket expense and that virtually all patients offered the self pay option have accepted. This demonstrates strong patient willingness to pay and reduces reliance on immediate reimbursement for early adoption. The combination of guideline support low out of pocket cost and positive clinical outcomes creates a self reinforcing cycle of demand that can sustain growth while reimbursement pathways are finalized.

The company reported a 26% year over year increase in total revenue for Q1 FY26 driven by new system placements and rising disposable probe sales indicating strong demand generation. North America sales surged 84% year over year with U.S. revenue up 31% year over year showing that the recent FDA clearance for low risk early breast cancer is translating into immediate commercial traction. The active U.S. account base expanded to 19 sites representing a 46% increase from the pre FDA clearance baseline of 13 accounts reflecting successful conversion of leads into paying customers. Management highlighted a robust pipeline of qualified leads generated at recent breast imaging and breast surgeon conferences which were significantly higher than in 2025 suggesting continued account growth in upcoming quarters.
The commercial organization is expanding through targeted hiring of sales representatives to increase geographic coverage and support the conversion of the growing lead pipeline into system installations. This expansion is designed to capture additional share within existing large health system networks where multiple units can be placed per account creating a recurring revenue stream from disposable probe usage. The company reported rising procedural activity at both new and existing sites which is a leading indicator of long term adoption and sticky revenue. By leveraging a model that does not require additional infrastructure or complex integration ProSense can be deployed quickly in outpatient clinics and community hospitals accelerating site onboarding.
The Choice post market study received FDA approval in March 2026 and will enroll 30 hybrid clinical and commercial sites across the United States with first patient enrollment expected before September 5 2026 and a target of 80 patients by March 2027. Approximately half of the planned sites are already active commercial accounts which reduces site activation risk and accelerates data collection. The study is designed to generate real world evidence that will confirm and potentially expand the indications granted by the ICE3 trial thereby strengthening the reimbursement narrative. Positive outcomes from the Choice study could facilitate broader guideline adoption and support future CPT1 and transitional pass through payment applications.
Reimbursement prospects are advancing with an established CPT code covering facility costs of about $4,000 per procedure and a CPT1 code submission planned for June 2026 with a decision anticipated in early 2027. An application for an additional $9,000 transitional pass through payment has been submitted and if approved would provide supplementary Medicare reimbursement starting in early 2027. The company expects Health Canada clearance before year end 2026 and Japan PMDA submission by Turumo in June or early Q3 FY26 with very positive pre submission discussions indicating a favorable outlook. Successful international approvals would open new high growth markets and diversify revenue beyond the United States.
Physician adoption is being bolstered by updated guidelines from the American Society of Breast Surgeons and the American Society of Breast Radiologists which now recommend cryoablation as an option for selected low risk breast cancer patients. Dr Richard Fine noted that in the absence of full reimbursement the overall procedure cost remains low enough for patients to manage an out of pocket expense and that virtually all patients offered the self pay option have accepted. This demonstrates strong patient willingness to pay and reduces reliance on immediate reimbursement for early adoption. The combination of guideline support low out of pocket cost and positive clinical outcomes creates a self reinforcing cycle of demand that can sustain growth while reimbursement pathways are finalized.

▼ Bear case

The company's revenue growth remains heavily dependent on the success of the CPT1 reimbursement application which is not expected to be decided until early 2027 creating a significant near term uncertainty for physician adoption and procedure volume. Without a permanent physician fee code many providers may hesitate to adopt ProSense despite low out of pocket costs because they cannot bill for their professional services limiting the addressable market. The transitional pass through payment application is also pending and approval is not guaranteed leaving the company reliant on the base $4,000 facility reimbursement which may be insufficient to drive broad hospital adoption. Any delay or denial in these reimbursement initiatives could stall the current growth trajectory and force a reassessment of commercial spending.
The active account base of 19 sites while showing a 46% increase from the pre FDA baseline is still a small fraction of the potential market and raises concerns about the scalability of the commercial model. Growth is currently concentrated in a limited number of large health networks and expanding beyond these early adopters may require a significantly larger sales force than the company is planning to hire. The reliance on a small group of key accounts increases exposure to customer concentration risk where a loss of a single major client could disproportionately affect revenue. Furthermore the seasonal slowdown noted by management during summer holidays could exacerbate quarterly volatility and hinder sequential growth.
International expansion faces regulatory uncertainty as the Health Canada amendment remains pending with only informal technical responses received and no guarantee of approval before year end 2026. The Japan submission through partner Turumo is still in preparation with a timeline of either June or early Q3 FY26 and while discussions have been described as very positive there is no assurance that PMDA will grant clearance without additional data or modifications. Delays in these markets would postpone the diversification benefit that management is counting on to reduce dependence on the United States. Moreover the company's current CE mark in Europe only covers breast cancer and expanding to other indications would require new clinical trials and regulatory submissions adding time and cost.
The Choice post market study while a positive step adds execution risk as the company must contract with 30 sites manage first patient enrollment before September 5 2026 and achieve 80 patient enrollment by March 2027 under clinical trial protocols. Any difficulties in site activation patient recruitment or data collection could delay the availability of real world evidence that is intended to support reimbursement expansion and indication broadening. The study's success is also contingent on maintaining the high response rates observed in the ICE3 trial and there is no guarantee that the post market cohort will replicate those outcomes. A failure to deliver compelling data could weaken the argument for CPT1 approval and reduce enthusiasm among guideline committees.
The company's reliance on disposable probe sales for recurring revenue creates vulnerability to pricing pressure and competition from alternative ablation technologies that may offer lower consumable costs or reusable platforms. If competitors introduce cost effective cryoablation or radiofrequency ablation solutions with superior economics the demand for IceCure's probes could erode affecting margins. Additionally the current probe pricing strategy has not been disclosed and any future price increases could be resisted by cost conscious hospitals especially in an environment where reimbursement remains limited. The lack of transparency around probe economics makes it difficult to assess the sustainability of the recurring revenue model.

The company's revenue growth remains heavily dependent on the success of the CPT1 reimbursement application which is not expected to be decided until early 2027 creating a significant near term uncertainty for physician adoption and procedure volume. Without a permanent physician fee code many providers may hesitate to adopt ProSense despite low out of pocket costs because they cannot bill for their professional services limiting the addressable market. The transitional pass through payment application is also pending and approval is not guaranteed leaving the company reliant on the base $4,000 facility reimbursement which may be insufficient to drive broad hospital adoption. Any delay or denial in these reimbursement initiatives could stall the current growth trajectory and force a reassessment of commercial spending.
The active account base of 19 sites while showing a 46% increase from the pre FDA baseline is still a small fraction of the potential market and raises concerns about the scalability of the commercial model. Growth is currently concentrated in a limited number of large health networks and expanding beyond these early adopters may require a significantly larger sales force than the company is planning to hire. The reliance on a small group of key accounts increases exposure to customer concentration risk where a loss of a single major client could disproportionately affect revenue. Furthermore the seasonal slowdown noted by management during summer holidays could exacerbate quarterly volatility and hinder sequential growth.
International expansion faces regulatory uncertainty as the Health Canada amendment remains pending with only informal technical responses received and no guarantee of approval before year end 2026. The Japan submission through partner Turumo is still in preparation with a timeline of either June or early Q3 FY26 and while discussions have been described as very positive there is no assurance that PMDA will grant clearance without additional data or modifications. Delays in these markets would postpone the diversification benefit that management is counting on to reduce dependence on the United States. Moreover the company's current CE mark in Europe only covers breast cancer and expanding to other indications would require new clinical trials and regulatory submissions adding time and cost.
The Choice post market study while a positive step adds execution risk as the company must contract with 30 sites manage first patient enrollment before September 5 2026 and achieve 80 patient enrollment by March 2027 under clinical trial protocols. Any difficulties in site activation patient recruitment or data collection could delay the availability of real world evidence that is intended to support reimbursement expansion and indication broadening. The study's success is also contingent on maintaining the high response rates observed in the ICE3 trial and there is no guarantee that the post market cohort will replicate those outcomes. A failure to deliver compelling data could weaken the argument for CPT1 approval and reduce enthusiasm among guideline committees.
The company's reliance on disposable probe sales for recurring revenue creates vulnerability to pricing pressure and competition from alternative ablation technologies that may offer lower consumable costs or reusable platforms. If competitors introduce cost effective cryoablation or radiofrequency ablation solutions with superior economics the demand for IceCure's probes could erode affecting margins. Additionally the current probe pricing strategy has not been disclosed and any future price increases could be resisted by cost conscious hospitals especially in an environment where reimbursement remains limited. The lack of transparency around probe economics makes it difficult to assess the sustainability of the recurring revenue model.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password